The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

Queen Elizabeth II Health Sciences Centre10 enrolled

Overview

The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Pertussis

Interventions

Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)BIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged 18-64 * BMT at the QEII Health Sciences Centre * BMT within last 12 months * Able to read and write English language * Able to give consent Exclusion Criteria: * Active infection * Active GVHD * Recent IVIG * Allergy to components of vaccine * Diphtheria or tetanus vaccination within 18 months

Outcomes

Primary Outcomes

Safety of the vaccine

Time frame: 28 days post-dose

Secondary Outcomes

Immunogenicity of vaccine

Time frame: 60 days post-dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.